Skip to main content

Table 1 Demographic and clinical characteristics of prostate cancer patients by tumor TMPRSS2-ERG gene fusion status.

From: Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

  TMPRSS2-ERG Gene Fusion Status
Characteristics Not Scored1 Positive Negative
  n = 158 n = 76 n = 138
Age at diagnosis    
   Mean (SD) 61.2 (7.4) 59.3 (6.3) 59.9 (7.2)
   Range 40 – 86 45 – 88 45 – 86
Gleason score (%)    
   2 - 7 (3+4) 138 (87.3) 63 (82.9) 115 (83.3)
   7 (4+3) - 10 17 (10.8) 12 (15.8) 19 (13.8)
   Missing 3 (1.9) 1 (1.3) 4 (2.9)
Stage (%)    
   Local 121 (76.6) 57 (75) 106 (76.8)
   Regional 37 (23.4) 18 (23.7) 29 (21.0)
   Distant 0 (0) 1 (1.3) 3 (2.2)
PSA value at diagnosis (ng/ml) (%)    
   0 – 9.9 92 (58.2) 52 (68.4) 91 (65.9)
   ≥ 10.0 41 (26.0) 16 (21.1) 29 (21.0)
   Missing 25 (15.8) 8 (10.5) 18 (13.1)
Vital status (%)    
   Alive 129 (81.7) 65 (85.5) 119 (86.2)
   Deceased    
Prostate cancer-specific death 4 (2.5) 6 (7.9) 6 (4.4)
Other cause of death 25 (15.8) 5 (6.6) 12 (8.7)
   Missing 0 (0) 0 (0) 1 (0.7)
Fusion Type    
   Translocation - 38 (50) -
   Deletion - 38 (50) -
Fusion Number    
   Single - 65 (85.5) -
   Multiple - 11 (14.5) -
Survival Time (years) (SD) 11.5 (2.6) 12.0 (2.6) 11.4 (3.1)
  1. 1Includes one equivocal case.